vTv Therapeutics Inc (VTVT)
18.50
+0.92
(+5.20%)
USD |
NASDAQ |
Jul 02, 16:00
18.50
0.00 (0.00%)
After-Hours: 19:21
vTv Therapeutics Research and Development Expense (Annual): 13.60M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 13.60M |
| December 31, 2022 | 12.36M |
| December 31, 2021 | 13.32M |
| December 31, 2020 | 11.02M |
| December 31, 2019 | 15.12M |
| December 31, 2018 | 23.04M |
| Date | Value |
|---|---|
| December 31, 2017 | 39.64M |
| December 31, 2016 | 45.75M |
| December 31, 2015 | 29.58M |
| December 31, 2014 | 18.73M |
| December 31, 2013 | 25.43M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
11.02M
Minimum
2020
15.12M
Maximum
2019
13.08M
Average
13.32M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Altimmune Inc | 65.80M |
| Viking Therapeutics Inc | 63.81M |
| Rhythm Pharmaceuticals Inc | 134.95M |
| NeuroBo Pharmaceuticals Inc | 9.158M |
| Omega Therapeutics Inc | 77.17M |